Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CSI-102
- Development stage
- Preclinical
- Lead developer
- Curigin
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
CSI-102 (also known as Csi102 or Csi-102) is a preclinical-stage gene therapy candidate being developed by Curigin for the treatment of hepatitis B. Utilizing Curigin's proprietary bi-specific siRNA platform, CSI-102 is designed to simultaneously target and inhibit the expression of both the hepatitis B virus (HBV) core protein and interleukin-6 (IL-6). The therapeutic payload is delivered via a viral vector (adenovirus) to achieve dual-gene silencing, aiming to suppress viral replication while mitigating the inflammatory response associated with chronic HBV infection.
- Other names
- Csi 102Csi102Csi-102
02
Targets
Interleukin-6 messenger RNAIL-6 (Interleukin 6)HBc (Hepatitis B virus core protein)Hepatitis B virus core messenger RNA
Beyond the preview
Go deeper on CSI-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CSI-102.